Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9415009 | BOND | Compositions, methods and systems for respiratory delivery of two or more active agents |
May, 2030
(7 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Jan 10, 2026 |
Drugs and Companies using ALBUTEROL SULFATE; BUDESONIDE ingredient
Market Authorisation Date: 10 January, 2023
Treatment: As-needed treatment or prevention of bronchoconstriction and reduction of the risk of exacerbations in patients with asthma 18 years of age and older
Dosage: AEROSOL, METERED;INHALATION
26
United States
10
Japan
9
Taiwan
8
Lithuania
8
Hungary
7
Russia
7
Korea, Republic of
7
Australia
6
Spain
6
Hong Kong
6
Denmark
6
Poland
6
China
6
Argentina
6
Croatia
6
Portugal
6
Slovenia
6
European Union
5
Cyprus
4
Mexico
3
Brazil
3
Canada
3
Ukraine
3
San Marino
3
Israel
3
South Africa
2
Norway
2
Luxembourg
1
Philippines
1
ME
1
Netherlands
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic